Altered hepatic gluconeogenesis during L-alanine infusion in weight-losinglung cancer patients as observed by phosphorus magnetic resonance spectroscopy and turnover measurements
S. Leij-halfwerk et al., Altered hepatic gluconeogenesis during L-alanine infusion in weight-losinglung cancer patients as observed by phosphorus magnetic resonance spectroscopy and turnover measurements, CANCER RES, 60(3), 2000, pp. 618-623
Profound alterations in host metabolism in lung cancer patients with weight
loss have been reported, including elevated phosphomonoesters (PMEs) as de
tected by P-31 magnetic resonance spectroscopy (MRS). In healthy subjects,
infusion of L-alanine induced significant increases in hepatic PMEs and pho
sphodiesters (PDEs) due to rising concentrations of 3-phosphoglycerate and
phosphoenolpyruvate, respectively, The aim of the present study was to moni
tor these changes in the tumor-free liver of lung cancer patients during L-
alanine infusion by means of simultaneous P-31 MRS and turnover measurement
s, Twenty-one lung cancer patients without liver metastases with (CaWL) or
without weight loss (CaWS), and 12 healthy control subjects were studied du
ring an i.v. L-alanine challenge of 1.4-2.8 mmol/kg followed by 2.8 mmol/kg
/h for 90 min. Plasma L-alanine concentrations increased during alanine inf
usion, from 0.35-0.37 mM at baseline to 5.37 +/- 0.14 mM in the CaWL patien
ts, 6.67 +/- 0.51 mM in the CaWS patients, and 8.47 +/- 0.88 mM in the cont
rols (difference from baseline and between groups during alanine infusion,
all P < 0.001). Glucose turnover and liver PME levels at baseline were sign
ificantly elevated in the CaWL patients. Alanine infusion increased whole-b
ody glucose turnover by 8 +/- 3% in the CaWS patients (P = 0.03), whereas n
o significant change occurred in the CaWL and controls. PME levels increase
d by 50 +/- 16% in controls (area under the curve, P < 0.01) and by 87 +/-
31% in the CaWS patients (P < 0.05) after 45-90 min, In contrast, no signif
icant changes in PME levels were observed in the CaWL patients. Plasma insu
lin concentrations increased during L-alanine infusion in all groups to lev
els that were lower in the CaWL patients than in the CaWS patients and cont
rols (P < 0.05), In lung cancer patients, but not in controls, changes in P
ME and PDE levels during alanine infusion mere inversely correlated with th
eir respective baseline levels (r = -0.82 and -0.86, respectively; P < 0.00
1). In addition, changes in PMEs during alanine infusion in lung cancer pat
ients were inversely correlated with the degree of weight loss (r = -0.54;
P < 0.05), This study demonstrates the presence of major alterations in the
pathway of hepatic gluconeogenesis in weight-losing lung cancer patients,
as shown by elevated glucose flux before and during L-alanine infusion, and
by the increased PME and PDE levels, which reflect accumulation of glucone
ogenic intermediates in these patients, Weight-stable lung cancer patients
show accelerated increases in PME and PDE levels during L-alanine infusion,
suggesting enhanced induction of the gluconeogenic pathway. Our results su
ggest altered gluconeogenic enzyme activities and elevated alanine uptake w
ithin the livers of weight-losing/weight-stable lung cancer patients.